Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Dalteparin sodium.

G F Pineo1, R D Hull

  • 1University of Calgary, Thrombosis Research Unit, Foothills Hospital, AB, Canada. jeanne.sheldon@crha-health.ab.ca

Expert Opinion on Pharmacotherapy
|October 5, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effect of extended-duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis.

Journal of thrombosis and haemostasis : JTH·2017
Same author

Apixaban after hip or knee arthroplasty versus enoxaparin: efficacy and safety in key clinical subgroups.

Journal of thrombosis and haemostasis : JTH·2013
Same author

Apixaban versus enoxaparin for thromboprophylaxis after hip or knee replacement: pooled analysis of major venous thromboembolism and bleeding in 8464 patients from the ADVANCE-2 and ADVANCE-3 trials.

The Journal of bone and joint surgery. British volume·2012
Same author

Chronic idiopathic thrombocytogenic purpura.

Canadian family physician Medecin de famille canadien·2011
Same author

Individual patient data meta-analysis of enoxaparin vs. unfractionated heparin for venous thromboembolism prevention in medical patients.

Journal of thrombosis and haemostasis : JTH·2011
Same author

Pooled analysis of trials may, in the presence of heterogeneity inadvertently lead to fragile conclusions due to the importance of clinically relevant variables being either hidden or lost when the findings are pooled.

Thrombosis research·2010
Same journal

Pharmacotherapeutic interventions for pediatric ulcerative colitis.

Expert opinion on pharmacotherapy·2026
Same journal

The rise and fall of TRPV1-targeted analgesia in osteoarthritis: a critical appraisal.

Expert opinion on pharmacotherapy·2026
Same journal

Dopamine transporter and beyond: evolving targets and combination strategies in stimulant use disorder.

Expert opinion on pharmacotherapy·2026
Same journal

GnRH antagonists for the treatment of fibroids and adenomyosis, current evidence and future perspectives.

Expert opinion on pharmacotherapy·2026
Same journal

Pharmacotherapeutic strategies for the management of congenital adrenal hyperplasia.

Expert opinion on pharmacotherapy·2026
Same journal

Current advances in pharmacotherapeutic strategies for the treatment of complicated intra-abdominal infections.

Expert opinion on pharmacotherapy·2026
See all related articles

Dalteparin sodium, a low molecular weight heparin, offers improved bioavailability and prolonged antithrombotic activity for preventing and treating thrombotic disorders. Its efficacy has led to international approval for various clinical indications.

Area of Science:

  • Pharmacology
  • Thrombosis Research

Background:

  • Dalteparin sodium is a low molecular weight heparin (LMWH) with advantages over unfractionated heparin (UFH).
  • Key benefits include enhanced bioavailability via subcutaneous injection and prolonged antithrombotic effects.
  • Its pharmacokinetic profile allows for once-daily administration, correlating with body weight.

Purpose of the Study:

  • To review the extensive clinical trial data for dalteparin sodium.
  • To assess its approved and investigational indications in thrombotic disorders.

Main Methods:

  • Analysis of data from numerous well-designed randomized clinical trials.
  • Evaluation of studies investigating dalteparin sodium in specific patient populations and conditions.

Main Results:

Related Experiment Videos

  • Dalteparin sodium is internationally approved for a broad range of indications, including post-surgery thromboembolism prevention.
  • Clinical trials have explored its use in maintaining graft patency, long-term deep vein thrombosis (DVT) treatment, upper extremity thrombosis prevention, and in pregnant patients.
  • Comparative studies with heparin for hemodialysis and hemofiltration show promising results, warranting further investigation.

Conclusions:

  • Dalteparin sodium is a well-established LMWH with proven efficacy in preventing and treating various thrombotic events.
  • Ongoing research continues to explore its potential in new clinical applications.
  • Further studies are needed to confirm its recommendation for indications like hemodialysis and hemofiltration.